Dr. Mark Paternoster holds the position of Senior Vice President, Development at Marinus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company. His role is centrally focused on leading development efforts for the company’s drug pipeline, particularly advancing therapies targeting pediatric epilepsies and related neurological disorders.
Professional Role and Responsibilities
Dr. Paternoster is responsible for overseeing clinical development initiatives, including strategy and execution to progress Marinus Pharmaceuticals’ product candidates through clinical trials. At the company’s Virtual R&D Event on October 5, 2021, he presented an overview of initiatives to advance a second-generation formulation of an investigational product, highlighting efforts to meet unmet needs in pediatric epilepsy. This indicates his direct involvement in both clinical planning and communication with stakeholders regarding pipeline progress.
Key aspects of his remit include:
- Designing and managing clinical development programs.
- Driving advancement of novel formulations after failure of existing treatment lines, with a protocol adjustment initiating study drug administration after the failure of one rather than two second-line antiepileptic drugs (AEDs), reflecting an emphasis on addressing patient populations with significant unmet medical need.
- Identifying opportunities to expand indications in pediatric epilepsy, a core focus therapeutic area for Marinus.
His presentations and leadership emphasize strategic prioritization of clinical pipeline diversification and portfolio expansion.
Company and Pipeline Context
Marinus Pharmaceuticals specializes in developing treatments for rare epilepsies and neurodevelopmental disorders, leveraging their core expertise in neuropharmacology. The company’s pipeline and development activities, as articulated by Dr. Paternoster, focus on second-generation formulations that could improve patient outcomes and broaden market opportunities, particularly within pediatric indications.
- The company strategy underscores a push to advance clinical trials while simultaneously exploring potential expansion opportunities in pediatric neurological diseases.
- The targeted disease areas have high unmet needs, making clinical development agility and innovative study designs critical—areas within Dr. Paternoster’s oversight.
Scientific and Clinical Expertise
Dr. Paternoster’s academic credentials (Ph.D.) and role suggest significant expertise in translational development, clinical pharmacology, and regulatory strategy for neurological drug candidates. His involvement in detailed R&D day presentations referenced by Marinus supports his technical leadership in driving clinical trial design and product lifecycle management.
Relevant Industry and Event Participation
- Leadership in presenting at investor and analyst-facing R&D events demonstrates his role as a key interface between development teams and external stakeholders.
- His insight into clinical unmet needs and regulatory considerations aligns with current industry trends toward expedited development for rare and pediatric diseases.
In summary, Mark Paternoster is a senior executive with specialized expertise in clinical development of neurological and pediatric epilepsy treatments at Marinus Pharmaceuticals. His leadership is instrumental in guiding the company’s second-generation product initiatives and clinical trial strategies, highlighting opportunities for portfolio growth in rare neurological diseases with unmet medical needs. This profile reflects a robust scientific and strategic development background aligned with the company’s focus on innovation in pediatric neurology therapeutics.
